Nasdaq · Healthcare
Tonix Pharmaceuticals Holding Corp. (TNXP)
As-reported financials and recent SEC filings for Tonix Pharmaceuticals Holding Corp., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$13.1M
Net income
$-124.0M
Net margin
—
Diluted EPS
$-14.57
ROE
-50.6%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $13.1M | $10.1M | $7.8M | — | — |
| Gross profit | $6.5M | $2.3M | $3.0M | — | — |
| Operating income | $-125.7M | $-136.7M | $-118.4M | $-112.1M | $-92.3M |
| Net income | $-124.0M | $-130.0M | $-116.7M | $-110.2M | $-92.3M |
| Diluted EPS | $-14.57 | $-14.72 | $-13.19 | $-13.21 | $-10.70 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
S-82026-07-01
View on EDGAR →8-K2026-06-29
View on EDGAR →42026-06-15
View on EDGAR →SCHEDULE 13G2026-06-15
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →8-K2026-06-08
View on EDGAR →8-K2026-05-27
View on EDGAR →Largest Healthcare peers
Go deeper on TNXP
Search Tonix Pharmaceuticals Holding Corp.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.